<DOC>
	<DOCNO>NCT00003981</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness E7070 treat patient solid tumor .</brief_summary>
	<brief_title>E7070 Treating Patients With Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose ( MTD ) E7070 administer adult patient solid tumor . - Determine qualitative quantitative toxic effect drug study predictability , duration , intensity , onset , reversibility dose relationship toxic effect patient population . - Propose safe dose phase II study . - Assess pharmacokinetics drug different dose level patient population . - Determine possible antitumor activity drug patient population . OUTLINE : This dose escalation study . Patients receive E7070 IV 1 hour day 1 , 8 , 15 , 22 . Treatment continue every 6 week least 2 course absence unacceptable toxicity disease progression . Cohorts 3-6 patient receive escalate dos E7070 escalate maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . Patients follow every 3 week . PROJECTED ACCRUAL : A total 30 patient accrue study 12 month .</detailed_description>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm solid tumor amenable standard therapy No brain involvement leptomeningeal disease PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 02 Life expectancy : At least 3 month Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9 g/dL Hepatic : Bilirubin le 1.5 mg/dL Liver function test great 2.5 time upper limit normal ( ULN ) ( great 5 time ULN liver metastasis present ) Renal : Creatinine great 1.4 mg/dL OR Creatinine clearance least 60 mL/min Other : Not pregnant nursing Fertile patient must use effective contraception No active bacterial infection ( e.g. , abscess fistula ) No nonmalignant disease precludes protocol therapy No history alcoholism , drug addiction , psychotic disorder preclude participation No glaucoma PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosoureas ) No concurrent antitumor drug Endocrine therapy : At least 4 week since prior anticancer hormonal therapy Radiotherapy : At least 4 week since prior radiotherapy ( 6 week extensive radiotherapy ) No concurrent radiotherapy ( except localize palliative radiotherapy ) Surgery : Not specify Other : No concurrent sulfonylurea agent diabetes antiarrhythmic agent No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>